COMPANY OVERVIEW

MeSCue-Janusys Inc. is a Biotech venture company addressing high unmet medical needs particularly in the field of periodontal and neurodegenerative diseases.

 
Our company aspires to improve the health of patients by commercially exploiting the therapeutic potential of our novel peptides.


We aim to fundamentally improve the quality of life for patients and helping to reduce overall healthcare costs by providing innovative therapies with our proprietary technologies.

 

Vision

to meet the unmet medical needs by using innovative therapies and diagnostic tools.

Mission

to bring innovative science and technology together for the development of effective and tolerable therapy

COMPANY STORY

2003

Janusys  incorporated as  independent spinoff of AIST*

2015

MeSCue  incorporated as  independent spinoff of AIST

2016

Janusys selected as one of 100 most innovative Japanese ventures

2017

MeSCue acquired Janusys and became MeSCue-Janusys

​Board of Directors

Koichiro Kitamura Ph.D.   

President & Chief Executive Officer (CEO)

Naoto Kagiyama Ph.D.

Executive Vice President & Founder

Yasushi Takagi

Director

Kazuo Hayakawa

Auditor

Managment & Scientific Advisors

Waleed Osman,  VMD, Ph.D.

Business Development Senior manager

Tai Kubo, Ph.D. 

Scientific Advisor, Ex-Deputy Director of "The Molecular Profiling Research Center for Drug Discovery (molprof), AIST"

Michio Oishi,  Ph.D.

Scientific Advisor, Chairman of “Kazusa DNA Research Institute”

Shigetaka Asano, MD, Ph.D.  

Scientific Advisor, Ex-Director of “The Institute of Medical Science Hospital”, The University of Tokyo

* AIST; National Institute of Advanced Industrial Science and Technology  is one of Japan’s largest and most innovative national institutes

Nihonbashi Life science Building2

707-3-chōme-11-5 Nihonbashihonchō, Chuo City, Tōkyō-to 103-0023

  • Picture1
  • Picture3
  • Google maps
  • White LinkedIn Icon

Copyright@2019 MeSCue-Janusys Inc. All Rights Reserved